Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Abbisko Cayman Limited ( (HK:2256) ) has issued an update.
Abbisko Cayman Limited announced promising longer-term efficacy and safety outcomes from its Phase III MANEUVER trial of pimicotinib, a CSF-1R inhibitor, for treating tenosynovial giant cell tumour (TGCT). Presented at ESMO 2025, the results showed significant and durable tumor response improvements, with a favorable safety profile, suggesting pimicotinib’s potential as a leading therapy in TGCT management. These findings enhance the drug’s commercial prospects and Abbisko’s position in the oncology market.
The most recent analyst rating on (HK:2256) stock is a Buy with a HK$22.00 price target. To see the full list of analyst forecasts on Abbisko Cayman Limited stock, see the HK:2256 Stock Forecast page.
More about Abbisko Cayman Limited
Abbisko Cayman Limited, through its subsidiary Abbisko Therapeutics, operates in the biotechnology industry, focusing on the development of novel therapeutics. The company specializes in creating small-molecule inhibitors for the treatment of various diseases, with a market focus on innovative cancer therapies.
Average Trading Volume: 5,704,949
Technical Sentiment Signal: Buy
Current Market Cap: HK$10.45B
For detailed information about 2256 stock, go to TipRanks’ Stock Analysis page.